Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynaecology,Oncology
Reference12 articles.
1. Possati-Resende JC, Fregnani JHTG, Kerr LM, Mauad EC, Longatto-Filho A, Scapulatempo-Neto C. The accuracy of p16/Ki-67 and HPV test in the detection of CIN2/3 in women diagnosed with ASC-US or LSIL. PLoS ONE. 2015;10(7):e0134445.
2. Sahasrabuddhe VV, Luhn P, Wentzensen N. Human papillomavirus and cervical cancer: Biomarkers for improved prevention efforts. Future Microbiol. 2011;6:1083–98.
3. Edgerton N, Cohen C, Siddiqui MT. Evaluation of CINtec PLUS® testing as an adjunctive test in ASC-US diagnosed SurePath® preparations. DiagnCytopathol. 2013;41:35–40.
4. Walker JL, Wang SS, Schiffman M, Solomon D. Predicting absolute risk of CIN3 during post-colposcopic follow-up: Results from the ASCUS-LSIL Triage Study (ALTS). Am J ObstetGynecol. 2006;195:341–8.
5. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand M-H, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26(6743):6744.